Logo
Login
$CUE
$18.45 -$0.21 (1.13%) Close

Company Executives

$CUE Management Team

Dr. Frank Morich

Independent Chairman of the Board

Age 71
Compensation $115.9K USD
Sex Male

Dr. Usman Azam

President

Chief Executive Officer

Director

Age 57
Compensation -
Sex Male

Mr. Colin Sandercock

Senior Vice President

General Counsel

Secretary

Age 68
Compensation $625.5K USD
Sex Male

Dr. Daniel Baker

Interim Chief Development Officer

Age 74
Compensation -
Sex Male

Ms. Lucinda Warren

Chief Financial and Business Officer

Age 57
Compensation -
Sex Female

Board of Directors

From the proxy statement filed Mar 16, 2026
Directors
5
serving now
Independent
Not stated
the proxy does not say
Average tenure
5.0 years
from year joined
CEO also chairs the board
No
Pasha Sarraf
Director Age On board Independent Committees Other public boards 2025 pay Source
Pasha Sarraf
Board chair
 56 2025
1 year
 Not stated None stated PolarityBio, Praesidia Biotherapeutics $88,080
Peter A. Kiener
73 2016
10 years
 Not stated
Compensation Committee · Chair
Peptone Switzerland AG, Ensocell Therapeutics $193,381
Frank Morich
72 2018
8 years
 Not stated
Audit Committee
Perspective Therapeutics $76,519
Pamela D. Garzone
71 2023
3 years
 Not stated
Compensation Committee
None stated $69,381
Patrick Verheyen
66 2023
3 years
 Not stated
Audit Committee Compensation Committee
None stated $76,881
Nominated to join at the meeting
Not on the board yet; they join only if elected.

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

3 disclosed in the proxy filed Mar 16, 2026
Affiliates of Bleichroeder LP
holder of more than 5% of our voting securities
$ 2,497,036
September 2024

Purchased shares and warrants in the September 2024 underwritten public offering

Open in proxy
Affiliates of Bleichroeder LP
holder of more than 5% of our voting securities
$ 2,498,657
April 2025

Purchased shares and warrants in the April 2025 underwritten public offering

Open in proxy
Affiliates of Bleichroeder LP
holder of more than 5% of our voting securities
$ 1,000,001
December 22, 2025

Purchased warrants in the December 2025 underwritten public offering

Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans